Caption Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Caption Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-35,000	Closed	-$3.76M	–	1498
2023 Q1	$3.76M	Sell	35,000 -115,200	-77%	-$13.3M	0.07%	295
2022 Q4	$16.5M	Buy	150,200 +136,200	+973%	+$8.83M	0.26%	93
2022 Q3	$826K	Hold	14,000	–	–	0.01%	928
2022 Q2	$395K	Buy	+14,000	New	+$406K	0.01%	1124
2022 Q1	–	Sell	-30,000	Closed	-$1.19M	–	2107
2021 Q4	$1.19M	Buy	+30,000	New	+$939K	0.01%	982

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Caption Management's RXDX Position: Q1 2023 in Review

Caption Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 81,209 shares — an estimated $9.35M sold.

Caption Management first reported a position in RXDX in Q4 2022 and held it in 1 quarter. The position peaked at $8.93M in Q4 2022. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

Caption Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Caption Management sold 81,209 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $9.35M.
Caption Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Caption Management's Prometheus Biosciences, Inc. Common Stock position peaked at $8.93M in Q4 2022.
219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on Caption Management's 13F filing for Q1 2023, filed 15 May 2023.